Clinical standards for the management of adverse effects during treatment for TB.

Singh, K P; Carvalho, A C C; Centis, R; D Ambrosio, L; Migliori, G B; Mpagama, S G; Nguyen, B C; Aarnoutse, R E; Aleksa, A; van Altena, R; Bhavani, P K; Bolhuis, M S; Borisov, S; van T Boveneind-Vrubleuskaya, N; Bruchfeld, J; Caminero, J A; Carvalho, I; Cho, J G; Davies Forsman, L; Dedicoat, M; Dheda, K; Dooley, K; Furin, J; García-García, J M; Garcia-Prats, A; Hesseling, A C; Heysell, S K; Hu, Y; Kim, H Y; Manga, S; Marais, B J; Margineanu, I; Märtson, A-G; Munoz Torrico, M; Nataprawira, H M; Nunes, E; Ong, C W M; Otto-Knapp, R; Palmero, D J; Peloquin, C A; Rendon, A; Rossato Silva, D; Ruslami, R; Saktiawati, A M I; Santoso, P; Schaaf, H S; Seaworth, B; Simonsson, U S H; Singla, R; Skrahina, A; Solovic, I; Srivastava, S; Stocker, S L; Sturkenboom, M G G; Svensson, E M; Tadolini, M; Thomas, T A; Tiberi, S; Trubiano, J; Udwadia, Z F; Verhage, A R; Vu, D H; Akkerman, O W; Alffenaar, J W C; Denholm, J T

doi:10.5588/ijtld.23.0078

Title

Clinical standards for the management of adverse effects during treatment for TB.

Publication Date

2023-07-01

Author(s)

Singh, K P

Carvalho, A C C

Centis, R

D Ambrosio, L

Migliori, G B

Mpagama, S G

Nguyen, B C

Aarnoutse, R E

Aleksa, A

van Altena, R

Bhavani, P K

Bolhuis, M S

Borisov, S

van T Boveneind-Vrubleuskaya, N

Bruchfeld, J

Caminero, J A

Carvalho, I

Cho, J G

Davies Forsman, L

Dedicoat, M

Dheda, K

Dooley, K

Furin, J

García-García, J M

Garcia-Prats, A

Hesseling, A C

Heysell, S K

Hu, Y

Kim, H Y

Manga, S

Marais, B J

Margineanu, I

Märtson, A-G

Munoz Torrico, M

Nataprawira, H M

Nunes, E

Ong, C W M

Otto-Knapp, R

Palmero, D J

Peloquin, C A

Rendon, A

Rossato Silva, D

Ruslami, R

Saktiawati, A M I

Santoso, P

Schaaf, H S

Seaworth, B

Simonsson, U S H

Singla, R

Skrahina, A

Solovic, I

Srivastava, S

Stocker, S L

Sturkenboom, M G G

Svensson, E M

Tadolini, M

Thomas, T A

Tiberi, S

Trubiano, J

Udwadia, Z F

Verhage, A R

Vu, D H

Akkerman, O W

Alffenaar, J W C

Denholm, J T

Type of document

Journal Article

OrcId

#PLACEHOLDER_PARENT_METADATA_VALUE#

DOI

10.5588/ijtld.23.0078

Abstract

BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE.METHODS: 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards.RESULTS: We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitivity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research.CONCLUSION: These standards provide a person-centred, consensus-based approach to minimise the impact of AE during TB treatment.

Link

link

Citation

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease 2023; 27(7)

Jornal Title

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease

ISSN

1815-7920

Austin Health

Files: